{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:47:48Z","timestamp":1795085268269,"version":"4.10.2"},"reference-count":135,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cpcardiol.2023.102350","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:16:17Z","timestamp":1703020577000},"page":"102350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-5185","authenticated-orcid":false,"given":"Reza Golchin","family":"Vafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Sabahizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramina","family":"Mofarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"3rd, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0002","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/cancers15010312","article-title":"Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity","volume":"15","author":"Sobiborowicz-Sadowska","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0003","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10741-020-09968-2","article-title":"Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment","volume":"26","author":"Saleh","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/HCO.0000000000000034","article-title":"Anthracycline-related cardiotoxicity in childhood cancer survivors","volume":"29","author":"Lipshultz","year":"2014","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.cpcardiol.2023.102350_bib0009","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10075","key":"10.1016\/j.cpcardiol.2023.102350_bib0010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(00)79001-4","article-title":"New paradigms for the treatment of cancer: the role of anti-angiogenesis agents","volume":"79","author":"Cherrington","year":"2000","journal-title":"Adv Cancer Res"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102350_bib0012","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0013","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/life12010048","article-title":"Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile","volume":"12","author":"Basak","year":"2022","journal-title":"Life"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/0003-4819-100-5-704","article-title":"Drugs five years later","volume":"100","author":"Loehrer","year":"1984","journal-title":"Cisplatin. Ann Intern Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0016","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/WCO.0b013e3282f1a06e","article-title":"Neurologic complications of chemotherapy agents","volume":"20","author":"Kannarkat","year":"2007","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0017","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1212\/CON.0000000000000943","article-title":"Neurotoxicity of cancer therapies","volume":"26","author":"Dietrich","year":"2020","journal-title":"Continuum"},{"issue":"18","key":"10.1016\/j.cpcardiol.2023.102350_bib0018","first-page":"5807","article-title":"Recent progress in the elucidation of the mechanisms of chemotherapy-induced cognitive impairment","volume":"25","author":"Alhowail","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0019","series-title":"Neurologic Complications of Chemotherapy, in Cancer Neurology In Clinical Practice: Neurologic Complications of Cancer and Its Treatment","first-page":"287","author":"Dietrich","year":"2008"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0020","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19830601)51:11<2035::AID-CNCR2820511113>3.0.CO;2-8","article-title":"Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma","volume":"51","author":"Meijer","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0021","first-page":"4151","article-title":"Management of nephrotoxicity of chemotherapy and targeted agents:","volume":"10","author":"Chiruvella","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0022","series-title":"Advances in Cancer Research","first-page":"77","article-title":"Chapter three - nephrotoxicity in cancer treatment: an update","author":"Chen","year":"2022"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","article-title":"A population-based study of cardiovascular mortality following early-stage breast cancer","volume":"2","author":"Abdel-Qadir","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/795602","article-title":"Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress","volume":"2015","author":"Angsutararux","year":"2015","journal-title":"Oxid Med Cell Longev"},{"issue":"30","key":"10.1016\/j.cpcardiol.2023.102350_bib0025","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","article-title":"Cardiotoxicity of cancer therapy","volume":"23","author":"Floyd","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102350_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11886-017-0873-7","article-title":"Cardiovascular risk in survivors of cancer","volume":"19","author":"Zheng","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2023.102350_bib0028","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"22","key":"10.1016\/j.cpcardiol.2023.102350_bib0029","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1161\/CIRCULATIONAHA.115.016704","article-title":"Anthracycline cardiotoxicity: a new paradigm for an old classic","volume":"131","author":"Groarke","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/21548331.2018.1530831","article-title":"Cardiotoxicity of cancer chemotherapy in clinical practice","volume":"47","author":"Jain","year":"1995","journal-title":"Hosp Pract"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/biomedicines11010181","article-title":"Cardiotoxicity of selected vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with renal cell carcinoma","volume":"11","author":"Franczyk","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0032","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0033","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1161\/ATVBAHA.121.316697","article-title":"Cardiotoxicity of cancer treatments: focus on anthracycline cardiomyopathy","volume":"41","author":"Nishi","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"10.1016\/j.cpcardiol.2023.102350_bib0034","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102350_bib0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0036","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.cpcardiol.2023.102350_bib0037","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2023.102350_bib0038","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.2014-0500","article-title":"Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors","volume":"20","author":"Serrano","year":"2015","journal-title":"Oncologist"},{"issue":"1099","key":"10.1016\/j.cpcardiol.2023.102350_bib0039","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/postgradmedj-2016-134286","article-title":"Alterations in the echocardiographic variables of the right ventricle in asymptomatic patients with breast cancer during anthracycline chemotherapy","volume":"93","author":"Abdar Esfahani","year":"2017","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/hearts2010005","article-title":"Diagnosis, prevention, treatment and surveillance of anthracycline-induced cardiovascular toxicity in pediatric cancer survivors","volume":"2","author":"Curren","year":"2021","journal-title":"Hearts"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0041","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0042","first-page":"539","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors","volume":"2","author":"Bhatia","year":"2020","journal-title":"JACC: CardioOncology"},{"issue":"23","key":"10.1016\/j.cpcardiol.2023.102350_bib0043","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the st. jude lifetime cohort study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0044","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1053\/j.jvca.2018.10.031","article-title":"A comparison of global longitudinal, circumferential, and radial strain to predict outcomes after cardiac surgery","volume":"33","author":"Zhang","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1213\/ANE.0000000000000088","article-title":"Perioperative assessment of myocardial deformation","volume":"118","author":"Duncan","year":"2014","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0046","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s12885-023-11261-y","article-title":"3D-based strain analysis and cardiotoxicity detection in cancer patients received chemotherapy","volume":"23","author":"Azzam","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0047","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s43044-020-00090-0","article-title":"The role of neurohormonal blockers in the primary prevention of acute-, early-, and late-onset anthracycline-induced cardiotoxicity","volume":"72","author":"Ayuna","year":"2020","journal-title":"Egypt Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0048","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.amjcard.2019.05.046","article-title":"Meta-analysis comparing usefulness of beta blockers to preserve left ventricular function during anthracycline therapy","volume":"124","author":"Shah","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0049","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6653971","article-title":"ECG markers of cardiovascular toxicity in adult and pediatric cancer treatment","author":"Sp\u00eenu","year":"2021","journal-title":"Dis Markers"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102350_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11864-019-0657-y","article-title":"QT interval prolongation associated with cytotoxic and targeted cancer therapeutics","volume":"20","author":"Chandrasekhar","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0051","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0052","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1078155219877931","article-title":"Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance","volume":"26","author":"Al-Malky","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0053","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.redox.2017.12.013","article-title":"MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2","volume":"15","author":"Zhao","year":"2018","journal-title":"Redox Biol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102350_bib0054","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am J Physiol Heart Circul Physiol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0055","article-title":"Understanding anthracycline cardiotoxicity from mitochondrial aspect","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102350_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091328","article-title":"Anthracyclines suppress both NADPH oxidase- dependent and -independent NETosis in human neutrophils","volume":"11","author":"Khan","year":"2019","journal-title":"Cancers"},{"issue":"38","key":"10.1016\/j.cpcardiol.2023.102350_bib0057","doi-asserted-by":"crossref","first-page":"11293","DOI":"10.1021\/bi971475e","article-title":"Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin","volume":"36","author":"V\u00e1squez-Vivar","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0058","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11906-010-0146-y","article-title":"Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage","volume":"12","author":"Geisberg","year":"2010","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0059","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/mol.105.013383","article-title":"Molecular pharmacology of the interaction of anthracyclines with iron","volume":"68","author":"Xu","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"15","key":"10.1016\/j.cpcardiol.2023.102350_bib0060","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1089\/ars.2020.8019","article-title":"Signaling pathways underlying anthracycline cardiotoxicity","volume":"32","author":"Sala","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0061","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0062","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cardiores.2005.08.014","article-title":"Autophagy in cardiac myocyte homeostasis, aging, and pathology","volume":"68","author":"Terman","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.06.007","article-title":"Autophagy and cancer therapy cardiotoxicity: from molecular mechanisms to therapeutic opportunities","volume":"1867","author":"Li","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0064","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/mol.119.115725","article-title":"Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring","volume":"96","author":"Wenningmann","year":"2019","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0065","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1096\/fj.03-0724rev","article-title":"The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage","volume":"18","author":"Fogli","year":"2004","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0066","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0067","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","article-title":"Involvement of ROS\/NLRP3 inflammasome signaling pathway in doxorubicin-induced cardiotoxicity","volume":"20","author":"Wei","year":"2020","journal-title":"Cardiovasc Toxicol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0068","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3390\/biom11111725","article-title":"Role of inflammation and redox status on doxorubicin-induced cardiotoxicity in infant and adult CD-1 male mice","volume":"11","author":"Reis-Mendes","year":"2021","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0069","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3390\/antiox10121897","article-title":"Endoplasmic reticulum stress promotes iNOS\/NO and influences inflammation in the development of doxorubicin-induced cardiomyopathy","volume":"10","author":"Bagchi","year":"2021","journal-title":"Antioxidants"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0070","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","article-title":"Doxorubicin and daunorubicin induce processing and release of interleukin-1\u03b2 through activation of the NLRP3 inflammasome: progress at a snail's pace","volume":"11","author":"Sauter","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0071","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12916-021-02185-0","article-title":"Ketone bodies: from enemy to friend and guardian angel","volume":"19","author":"Kolb","year":"2021","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0072","first-page":"14","article-title":"Lipid peroxidation and activity of diagnostically significant enzymes in cosmonauts after flights of various durations","volume":"31","author":"Markin","year":"1997","journal-title":"Aviakosm Ekolog Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0073","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/bst024375s","article-title":"Identification of pro-oxidant or antioxidant characteristics of proteins and enzymes in membranes; use of liposome-entrapped proteins and other thiol-containing compounds","volume":"24","author":"Straghan","year":"1996","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0074","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4329\/wjr.v8.i11.880","article-title":"Mechanisms underlying (18)F-fluorodeoxyglucose accumulation in colorectal cancer","volume":"8","author":"Kawada","year":"2016","journal-title":"World J Radiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s12350-019-01617-y","article-title":"Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity","volume":"27","author":"Kim","year":"2020","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0076","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102350_bib0077","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0078","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of \u03b2-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0079","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3892\/etm.2014.1863","article-title":"Cardioprotective effect of carvedilol: inhibition of apoptosis in H9c2 cardiomyocytes via the TLR4\/NF-\u03baB pathway following ischemia\/reperfusion injury","volume":"8","author":"Zhao","year":"2014","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0081","first-page":"36","article-title":"Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia","volume":"7","author":"Vachhani","year":"2017","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0082","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0083","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0084","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-020-00078-4","article-title":"Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardio-oncology"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.freeradbiomed.2021.03.045","article-title":"Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases","volume":"169","author":"Bartekov\u00e1","year":"2021","journal-title":"Free Radical Biol Med"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.867867","article-title":"An olive oil mill wastewater extract improves chemotherapeutic activity against breast cancer cells while protecting from cardiotoxicity","volume":"9","author":"Benedetto","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0087","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/annonc\/mdu250","article-title":"Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis","volume":"26","author":"Schmid","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.cpcardiol.2023.102350_bib0088","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021580","article-title":"Efficacy of physical exercise to offset anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of clinical and preclinical studies","volume":"10","author":"Naaktgeboren","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2023.04.010","article-title":"Feasibility of aerobic exercise training to mitigate cardiotoxicity of breast cancer therapy: a systematic review and meta-analysis","author":"Tsai","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0090","first-page":"15","article-title":"Anthracycline\u2011induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment","volume":"11","author":"Cai","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0091","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s10741-020-09968-2","article-title":"Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment","volume":"26","author":"Saleh","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0092","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"22","key":"10.1016\/j.cpcardiol.2023.102350_bib0093","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2023.102350_bib0094","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2023.102350_bib0095","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0096","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/dom.14158","article-title":"Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG OUTCOME trial","volume":"22","author":"Wanner","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102350_bib0097","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cpcardiol.2023.102350_bib0098","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0099","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2023.04.002","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: a meta-analysis of randomized controlled trials","author":"Fan","year":"2023","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0102","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0103","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias","volume":"9","author":"Gao","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102350_bib0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031678","article-title":"SGLT2 inhibitors and their antiarrhythmic properties","volume":"23","author":"Kolesnik","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.cpcardiol.2023.102350_bib0106","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0107","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"15","key":"10.1016\/j.cpcardiol.2023.102350_bib0108","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hrtlng.2023.02.009","article-title":"SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: a meta-analysis of randomized controlled trials","volume":"59","author":"He","year":"2023","journal-title":"Heart Lung"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/ndt\/gfz294","article-title":"The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the effects of empagliflozin on cardiac structure, function, and circulating biomarkers in patients with type 2 diabetes CardioLink-6 trial","volume":"35","author":"Opingari","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0111","series-title":"Effects of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors on Non-Alcoholic Fatty Liver Disease\/Non-Alcoholic Steatohepatitis: Ex quo et quo vadimus?","author":"Katsiki","year":"2019"},{"issue":"17","key":"10.1016\/j.cpcardiol.2023.102350_bib0112","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.cpcardiol.2023.102350_bib0113","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0114","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.102350_bib0115","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12012-021-09665-y","article-title":"Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways","volume":"21","author":"Bar\u0131\u015f","year":"2021","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102350_bib0116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0117","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664181","article-title":"Sodium-glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of ampk-mtor signaling pathway-mediated autophagy","volume":"12","author":"Ren","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121207","article-title":"Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis","volume":"312","author":"Min","year":"2023","journal-title":"Life Sci"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.102350_bib0119","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovascular Diabetol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102350_bib0121","first-page":"1461","article-title":"Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation","volume":"396","author":"Hu","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102350_bib0122","doi-asserted-by":"crossref","DOI":"10.3390\/biology9110369","article-title":"TLR9 binding to Beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity","volume":"9","author":"Wang","year":"2020","journal-title":"Biology"},{"issue":"20","key":"10.1016\/j.cpcardiol.2023.102350_bib0123","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207802","article-title":"NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells","volume":"21","author":"Quagliariello","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11S","key":"10.1016\/j.cpcardiol.2023.102350_bib0124","doi-asserted-by":"crossref","first-page":"A1830","DOI":"10.1016\/S0735-1097(18)32371-4","article-title":"Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-\u03bb, tumor necrosis factor-\u03b1, interleukin-6: Possible mechanism of decreasing cardiovascular risk in diabetes mellitus","volume":"71","author":"Tan","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.102350_bib0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0126","first-page":"1","article-title":"Empagliflozin significantly prevents QTc prolongation due to amitriptyline intoxication","volume":"34","author":"Bar\u0131\u015f","year":"2023","journal-title":"Cardiovasc J Afr"},{"issue":"8","key":"10.1016\/j.cpcardiol.2023.102350_bib0127","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0128","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","author":"Abdel-Qadir","year":"2023","journal-title":"JACC: CardioOncology"},{"key":"10.1016\/j.cpcardiol.2023.102350_bib0129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.18433\/jpps32879","article-title":"Exploring the role of sodium-glucose cotransporter as a new target for cancer therapy","volume":"25","author":"Bardaweel","year":"2022","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102350_bib0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2023.102350_bib0131","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cpcardiol.2023.102350_bib0132","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0133","doi-asserted-by":"crossref","first-page":"13472","DOI":"10.1038\/s41598-021-92925-2","article-title":"A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus","volume":"11","author":"Mukai","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102350_bib0134","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obesity Metabolism"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102350_bib0135","article-title":"Atrial fibrillation is associated with increased mortality in patients undergoing transcatheter aortic valve replacement: insights from the placement of aortic transcatheter valve (PARTNER) trial","volume":"9","author":"Biviano","year":"2016","journal-title":"Circul: Cardiovas Intervent"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623007673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623007673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:34:24Z","timestamp":1758940464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623007673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":135,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0146280623007673"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102350","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102350"}}